ADP
|
Basic information |
| Metabolite name | ADP |
 | HMDB0001341 |
 |
C00008 |
 |
6022 |
| Synonyms | Adenosine-5-diphosphate; |
| No. of studies | 10 |
|
Basic information |
| Metabolite name | ADP |
| HMDB0001341 |
|
C00008 |
|
6022 |
| Synonyms | Adenosine-5-diphosphate; |
| No. of studies | 10 |
|
Relationship between ADP and depression (count: 10) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M050 | Type3 | 24h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Prefrontal cortex | Cynomolgus monkey | Up |
| Study M458 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Ventral hippocampus | C57BL/6 J mouse | Up |
| Study M651 | Type1 | LPS group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M651 | Type2 | LPS + fish oil group vs. LPS group | Brain | C57BL/6 mouse | Up |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Down |
| Study M768 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M768 | Type2 | depression group, after vs. before fluoxetine treatment | Serum | Human | Down |
| Study M863 | Type1 | CSDS group vs. control group | Medial prefrontal cortex | C57BL/6J mouse | Down |
| Study M863 | Type2 | CSDS+ edaravone group vs. CSDS group | Medial prefrontal cortex | C57BL/6J mouse | Up |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |